Sygnature Chemical Services, a leading provider of premium medicinal chemistry and computational chemistry services to the global pharmaceutical industry, and Heptares Therapeutics, a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), have announced that they have entered into a contract chemistry collaboration in drug discovery.
Under the terms of the agreement scientists from the two companies are working together to advance one of Heptares’ internal high-value GPCR programmes. Sygnature is providing synthetic chemistry services to produce a novel chemical library for Heptares to evaluate against purified, stabilised and functional proprietary GPCR targets (known as StaRs™, stabilised receptors).
Commenting on the agreement, Dr Simon Hirst, Sygnature’s CEO, said, “We are delighted that Heptares has chosen to collaborate with Sygnature on this programme. Heptares’ decision to work with us demonstrates our growing reputation for delivering ‘top tier’ science coupled with high value and quality. Over the past five years Sygnature has established an excellent track record of success and enjoyed healthy growth because of its ability to deliver flexible scientific resource and drug discovery expertise, without high overhead costs. We look forward to building a long-term scientific and business relationship with Heptares.”
Dr Miles Congreve, head of chemistry at Heptares, said, “We are working with Sygnature on this drug discovery programme which forms a component of our efforts to develop novel GPCR-focused therapeutics. Sygnature is becoming well-known and respected within the pharmaceutical industry for its high-quality medicinal and synthetic chemistry driven services. Sygnature was therefore our choice as a trusted partner to leverage our own internal drug discovery capabilities.”